Systems and Methods for Automated Treatment Recommendation Based on Pathophenotype Identification

A method comprising:

• administering, with an invasive cardiopulmonary exercise testing (iCPET) system, an iCPET test to a subject;
• during the administration of the iCPET test, continuously collecting and storing iCPET data captured in real-time by the iCPET system;
• with a computer processor, analyzing values of one or more variables of the iCPET data using network analysis to identify an exercise pathophenotype of the subject;
• with the computer processor, assigning the subject to a cohort based on the identified exercise pathophenotype;
• with the computer processor, determining a recommended course of treatment based on the cohort to which the subject has been assigned;
• and
• presenting the recommended course of treatment on an electronic display.

A system comprising:

• an invasive cardiopulmonary exercise testing (iCPET) system that administers an iCPET study on a subject and that generates values for a plurality of variables for the subject during the administration of the iCPET study;
• and
• a computer system that is communicatively coupled to the iCPET system, the computer system comprising:
• a memory;
• an electronic display;
• and
• a processor that executes instructions stored in the memory for:
• receiving, from the iCPET system, the values for the plurality of variables;
• analyzing the values of the plurality of variables using network analysis to identify an exercise pathophenotype of the subject;
• assigning the subject to a cohort based on the identified exercise pathophenotype;
• determining a recommended course of treatment based on the cohort to which the subject has been assigned;
• and
• presenting the recommended course of treatment on the electronic display, wherein the recommended course of treatment includes initiation of pharmacotherapeutic intervention including treatment with a predetermined class of cardiovascular drugs that can be classified to ten categories based on the features, including, but not limited to pulmonary vasodilator therapy, pulmonary arterial hypertension treatment, peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant and thrombolytic agent, and cardiac tonic therapeutic agents including, but not limited to beta blockers and calcium channel blockers.